Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinomain situ
- 1 March 1991
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 18 (1) , 11-17
- https://doi.org/10.1007/bf01975438
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Discrepancies between flow cytometric and cytogenetic studies in the detection of aneuploidy in human solid tumorsCytometry, 1990
- An immunohistochemical study of the presence of c‐erbB‐2 protein in Paget's disease of the nippleHistopathology, 1989
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Prediction of Relapse or Survival in Patients with Node-Negative Breast Cancer by DNA Flow CytometryNew England Journal of Medicine, 1989
- Neu-Protein Overexpression in Breast CancerNew England Journal of Medicine, 1988
- Proliferative index of breast carcinoma by thymidine labeling: Prognostic power independent of stage, estrogen and progesterone receptorsBreast Cancer Research and Treatment, 1988
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Cell kinetics of histologic variants ofin situ breast carcinomaBreast Cancer Research and Treatment, 1986
- Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancerBreast Cancer Research and Treatment, 1986
- In VitroLabeling of Solid Tissues with Tritiated Thymidine for Autoradiographic Detection of S-Phase NucleiStain Technology, 1977